SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 188.41-2.4%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: growthvalue who wrote (25841)9/29/1998 3:35:00 PM
From: aknahow  Read Replies (2) of 32384
 
GV, we live in a world of the doable. There is little value in wishing for things that can't be done. A straight debt offering could not be made. Even a straight junk bond or high yield bond can't be issued. Straight debt means it will be paid off, and while projections of future earnings are fine for equity holders I have yet to see a debt issue without projection of ability to finance and repay made on historic, actual, earnings as well as collateral.

Biotechs burn cash. As you point out, floorless convertibles are less than desirable. Given the difficulties of obtaining continuous funding I think management deserves some credit for putting this deal together. I do not know if looking at acquisitions of other drugs or mergers will be good for LGND. However, I would rather have management at least consider these uses of capital than not consider them at all. Did it make sense to license ELAN's drug? Don't know but as was pointed out this was a minor part of the deal. It was perhaps something both sides thought helped the deal work and i would have trouble thinking that it was really of critical importance in determining if this financing was a good deal for LGND.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext